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StreptozotocinGlucose metabolism and insulin signaling disruptions in the brain have been proposed as a likely etiology of
Alzheimer's disease. The aim of the present study was to investigate the time course of cognitive impairments
induced by intracerebroventricular injection of streptozotocin (STZ) in rats and correlate them with the en-
suing neurodegenerative process. Early and late effects of STZ were evaluated by using the reference and
working memory versions of the Morris' water maze task and the evaluation of neurodegenerative markers
by immunoblotting and the Fluoro-Jade C histochemistry. The results revealed different types of behavioral
and neurodegenerative responses, with distinct time courses. We observed an early disruption on the work-
ing memory as early as 3 h after STZ injections, which was followed by degenerative processes in the hippo-
campus at 1 and 15 days after STZ injections. Memory disruption increases over time and culminates with
signiﬁcant changes in amyloid-beta peptide and hyperphosphorylated Tau protein levels in distinct brain
structures. These ﬁndings add information on the Alzheimer's disease-like STZ animal model and on the
mechanisms underlying neurodegenerative processes.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.: +55 11 3091 7426.
evier OA license.
Flow chart 1. Flow chart diagramming the scheme of experimental procedures. A.
Early procedure. B. Late procedure.
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Alzheimer's disease (AD) is one of the most common causes of de-
mentia in aged humans. It is clinically characterized by a general and
progressive cognitive decline, especially memory deterioration. Most
cases have a sporadic occurrence, and aging seems to be the main
risk factor [1]. Typical neuropathological hallmarks of AD include
both accumulations of senile plaques, corresponding to deposits of
amyloid-β (Aβ) peptide outside of neurons, and neuroﬁbrillary tangles
(NFT), corresponding to intracellular deposits of hyperphosphorylated
Tau protein. Post mortem studies of AD patients reveal neuronal loss in
the hippocampus, enthorinal cortex, amygdala, neocortex, and subcor-
tical areas, including basal forebrain cholinergic neurons, dorsal raphe
serotonergic neurons and locus coeruleus noradrenergic neurons [1].
Not surprisingly, the earliest symptoms of AD include explicit memory
deﬁcits, particularly when navigating in both familiar and unfamiliar
environments [2], and disruption of executive functions, including
working memory [1,3].
Molecular evidence raised the assumptions that trafﬁcking of the
amyloid precursor protein (APP) is under control of insulin signaling
and insulin receptor tyrosine kinase [4,5] and that insulin regulates
phosphorylation of tau protein via glycogen synthase kinase-3 activi-
ty [6,7]. In addition, insulin affects brain functions such as cognition
and memory as shown by in vivo studies [8]. Functional studies
have shown disruption in both cerebral glucose mobilization and en-
ergy metabolism either preceding or accompanying the initial stages
of cognitive impairments in AD [9,10]. Accordingly, impairments of
glucose metabolism and of the insulin signaling pathway have been
proposed as a likely etiology of AD [5,9,11,12]. Indeed, behavioral
changes reported in animal models of diabetes or Alzheimer's disease
include disruption of performance in the reference memory version
of the Morris' water maze spatial navigation task, the elevated plus
maze, and the T-maze footshock avoidance paradigm [13–16]. Re-
cently, Bird and colleagues [17] demonstrated that patients with
mild AD exhibit impairments on topographical short-term memory
even for very short periods of time, but not on non-spatial aspects
of the landscapes. These data lead the authors to propose that “this
memory function is particularly sensitive to the earliest stages of
the disease”. Thus, behavioral results involving animal models of AD
tested in the Morris' water maze task seem to be particularly relevant
since this task evaluates spatial navigation, particularly when the an-
imal is trained departing from different starting locations [18,19].
Therefore, on considering Bird and colleagues [17], it would be even
more relevant to evaluate spatial navigation in animal models of AD
by using a working memory version of the task, as that reported by
Xavier and colleagues [19].
Intracerebroventricular (icv) injections of the diabetogenic drug
streptozotocin (STZ), often employed to induce experimental diabe-
tes mellitus in animals, have been used to investigate abnormalities
of brain glucose metabolism [20–22] and thus for inducing an
AD-type neurodegeneration. Biochemical, morphological and behav-
ioral changes that follow icv injection of STZ in rodents seem to be
equivalent to those seen in sporadic AD. For instance, STZ injection
causes a reduction of glucose utilization and glycogen metabolism
[23,24], impairments of insulin and insulin-like growth factor signal-
ing [20,25], and impairments in the performance in memory tasks
[21,26–29].
Even though performance in the reference memory version of
Morris' water maze task is sensitive to STZ icv injection [26], that be-
havioral task does not seem to be the best alternative to evaluate both
the early cognitive changes that follow administration of STZ in this
animal model of AD and the progression of these symptoms, since it
requires several days of training to be acquired and performance is
maintained relatively stable for months after acquisition. In contrast,
the working memory version of the Morris' water maze task, as de-
scribed by Xavier et al. [19], appears to be a more suitable behavioraltest to investigate the progression of symptoms following icv injec-
tion of STZ.
Thus, the aim of present study was to investigate the time course
of cognitive impairments induced by a single icv injection of STZ in
rats and to correlate them with the ensuing neurodegenerative pro-
cess. While the behavioral effects of STZ icv injection were evaluated
by using reference and workingmemory versions of the Morris' water
maze task, the expression of neurodegenerative markers was evaluat-
ed by immunoblotting and the Fluoro-Jade C histochemistry.
2. Methods
2.1. Subjects
Adult male Wistar rats, weighing 250–350 g at the beginning of
the experiments, obtained from the animal facilities of the Institute
of Biomedical Sciences, University of São Paulo, were used in this
study. The animals were housed in groups of 3–4 animals per conven-
tional cage, maintained at 23 °C±2, in a 12 h light/12 h dark cycle
(lights on at 06:00 h), with free access to food and water. These hous-
ing conditions lasted until the end of the experiments. The experi-
ments were carried out in accordance with the guidelines of the
Brazilian College for Animal Experimentation (COBEA) and were ap-
proved by The Ethics Committee for Animal Research of the Institute
of Biomedical Sciences, University of São Paulo (Protocol no 33/08/
CEUA), which comply with national and international procedures of
care of animals used in scientiﬁc research.
Independent groups of rats were used to investigate the early
(Flow chart 1, part A) and late (Flow chart 1, part B) effects of STZ
icv injection and the surgical procedures in each of these cases dif-
fered (see below). A third group of rats was used for histochemical
analysis of neurodegeneration by the Fluoro-Jade C method.
2.2. Stereotaxic surgical procedure
Rats were anesthetized with an i.m. combination of ketamine
(5 mg/100 g of body weight, b.w.) and xylazine (1 mg/100 g b.w.)
and positioned in a stereotaxic frame.
In order to test early effects of STZ icv injection, a group of
pre-trained (see Section 2.4) rats received permanent bilateral im-
plants of 13-mm-long 23-gauge guide cannulae, positioned according
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1.5 mm, and DV=3.5 mm [30]. The implanted guide cannulae
allowed later injection of either STZ (N=7) or citrate buffer (vehicle,
N=5), by way of a 30-gauge infusion cannulae 13 mm long, when
the subjects were awake and freely moving, thus allowing to follow
behavioral changes after injection (see below).
In order to test late effects of STZ icv injection, rats without any
pre-surgical behavioral training were subjected to bilateral injec-
tions of either STZ (3 mg/kg, b.w., Sigma, St. Louis, MO) freshly
dissolved in citrate buffer (0.05 mol/L, pH 4.5; N=9) or the same
volume of vehicle (control group, CTR; N=9) at the same stereo-
taxic coordinates. A volume of 4 μl was injected in each hemisphere
by way of glass micropipettes with tips ranging from 10 to 20 μm,
coupled to a pressure system. After injections, there was a 4-day
recovery period before the beginning of behavioral testing (see
Section 2.5), and after that, those subjects were used for immuno-
blotting analysis (see Section 2.6).
Histochemical analysis of neurodegeneration by the Fluoro-Jade C
method was run in a group of rats subjected to this later surgical
method (N=21).
2.3. Morris' water maze apparatus and general procedures of reference
and working memory
The Morris' water maze apparatus and the procedures employed
were similar to those described by Xavier and colleagues [19]. The
pool was a round, black ﬁberglass tank, 200 cm diameter, 50 cm
height, ﬁlled to a depth of 25 cm with water (26 °C±1), rendered
opaque by the addition of milk. A movable circular plastic platform
9 cm in diameter, mounted on a plastic column, was placed in the
pool about 2 cm below the water surface. The platform location
depended on the behavioral testing procedure (see below). For de-
scriptive data analysis, the pool was divided into four equal-area
quadrants which bordered each other along imaginary lines which
intersected the edge of the pool at the arbitrary cardinal start loca-
tions. The time spent within the training counter (an area three
times the platform diameter, surrounding each platform position),
as well as the number of entries within the counter, provided speciﬁc
indexes of spatial location. The percentage of time spent within a
33-cmwide ring containing the platform (the critical ring), which ex-
ternal border was 33 cm distant from the pool border, helped to ana-
lyze the spatial bias of the animals in the pool. The swimming pool
was located in a 3.15×4.00 m room with several salient cues hanging
on the walls. A video camera positioned approximately 290 cm over
the center of the pool was connected to a video-tracking digitizing
device (VP112, HVS Image Ltd., Hampton, UK) and sampled in units
of 0.1 section by a computer system programmed to collect and ana-
lyze the animals' swim paths. Each trial in both the reference and the
working memory versions of the task constituted placing the rat near
the border of the pool (in one of the starting locations) and allowing it
to swim until the platform was found. If the rat did not ﬁnd the plat-
form within 120 s, the animal was then manually guided to the plat-
form, where it remained for a 10-s period.
In the water maze reference memory training task, the platform
was located in a single, ﬁxed position in the center of the critical
quadrant. Each animal was exposed to four trials per session (one ses-
sion a day), with an intertrial interval (ITI) of 10 min. Acquisition of
the reference memory task was assessed by decreases of latency
and path length, and both by increases of the percentage of time
spent in the quadrant and by increases of the percentage of time
spent within the ring where the platform was located. Training
proceeded until the subjects reached an asymptotic level of
performance.
A probe test, with the platform removed, was conducted 24 h after
the end of the reference memory training phase. During this test, the
animals were allowed to swim freely in the pool for 3 min. Thepercentage of time the animal spent within the critical quadrant rel-
ative to the other quadrants, the amount of time the animal spent
within the counter, and the number of times the animal swam across
that counter (counter frequency), in three time bins of 60 s each,
allowed assessment of long-term memory for platform location
through the extent of spatial bias in the ﬁrst time bin, and evaluation
of the rate of extinction of this behavior by comparing the same pa-
rameter over the three consecutive time bins.
In the water maze working memory task, the animals were tested
along four trials per session. The platform location was changed from
session to session. Therefore, on the ﬁrst trial of each session the sub-
jects had to ﬁnd the platform by scanning the pool. Then, on the sec-
ond and remaining trials, the subjects could use the information
about the platform location acquired in the previous trials in order
to improve their performance along trials. The ITI could be either
10 min (ITI=10) or 0 min (ITI=0), thus stimulating maintenance
of the critical information about the platform location for variable pe-
riods of time in each session. Maintenance of information about the
platform location in working memory was assessed by decreases of
latency and path length along trials within a session. When testing in-
volved one session per day, the time spent within the critical previous
session counter and the critical previous session counter frequency
provided a 24-h delay test of memory for the precise former platform
location [19].2.4. Behavioral pre-injection training and post-injection testing soon
after STZ administration (early effects)
Evaluation of early effects (see Flow chart 1, part A) of STZ on
spatial working memory required training the subjects prior to the
STZ injection. These pre-STZ injection procedures included (1) 5 ses-
sions of pre-surgical training in the reference memory task, (2) exe-
cution of a surgery for implantation of the guide cannulae to be later
used for administration of STZ, (3) a post-surgical 5-day recovery
period, (4) 3 sessions of post-surgical training in the reference mem-
ory task, (5) one Probe Test session, and (6) 2 sessions of training in
the working memory task, with an ITI of 10 min, in this sequence.
These procedures led to complete acquisition of the spatial working
memory task and, in addition, provided data of the subjects' pre-STZ
injection level of performance in this task; this allowed allocation
of the subjects for the groups (see below) according to their
pre-injection performance, thus rendering homogeneity among the
groups before the critical treatments. Twenty-four hours later,
either STZ or vehicle (in the same dose and volume as described
above) was injected bilaterally, along 5 min, via infusion cannulae
inserted into the guide cannulae; the infusion cannulae was
connected to a polyethylene tube connected to a Hamilton micro-
syringe. Then, the subjects were exposed to successive sessions of
testing in the working memory version of the water maze task,
with ITI=10 min. These sessions were run 0.5, 1, 2, 3, 4 and 24 h
after the injection, thus allowing the follow up of the time course
of cognitive disruption.2.5. Post-injection behavioral testing of late effects of a single dose of STZ
After the 4-day period of surgery recovery (see Flow chart 1 part
B), the subjects were exposed to (1) 7 sessions of training in the spa-
tial reference memory version of the water maze task, (2) a Probe
Test session, (3) 5 sessions of testing in the spatial working memory
version of the water maze task, with ITI=10, and (4) one session of
testing in the spatial working memory version of the task, with
ITI=0, in order to evaluate performance of the subjects when the
time required for maintenance of the spatial information in working
memory was virtually zero.
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Thirty days after the injections, the subjects involved in evaluation
of the late behavioral effects of STZ and corresponding controls were
decapitated under administration of an overdose of anesthesia and
the brain rapidly collected and dissected. The enthorinal cortex, neo-
cortex, basal ganglia, hippocampus, and hypothalamus, were individ-
ually collected, and homogenized in extraction buffer at 4 °C (Tris, pH
7.4, 100 mM; EDTA 10 mM; PMSF 2 mM; aprotinin 0.01 mg/ml). The
protein concentration of the samples was determined by a protein
assay (Bio-Rad, Hercules, CA, USA), and 50 μg of protein were
subjected to 10% SDS-PAGE gel and electrotransferred to nitrocellu-
lose membranes using a Trans-Blot cell system (Bio-Rad). The nitro-
cellulose membranes were then blocked and incubated overnight
with a rabbit polyclonal antiserum against Aβ (H-43; Santa Cruz
Technology, Santa Cruz, CA, USA), a mouse monoclonal antibody
against Tau, a rabbit polyclonal antiserum against phosphorylated-
Tau (pSer199/202; Sigma), a mouse monoclonal antibody against glial
ﬁbrillary acidic protein (GFAP; Sigma), and a goat polyclonal
antiserum against the synthesizing enzyme of acetylcholine, choline
acetyltransferase (ChAT; Chemicon, Temecula, CA, USA). A loading
control was conducted in all experiments by using an anti-GAPDH an-
tibody (Santa Cruz). Speciﬁcally bound antibody was visualized using
a chemiluminescence kit (ECL Kit; Amersham Biosciences, Little
Chalfont, Buckinghamshire, United Kingdom). Finally, the blots were
densitometrically analyzed with Scion Image 4.0.2 (Scion Corpora-
tion, Frederick, MD).
2.7. Histochemical analysis by Fluoro-Jade C
After 1, 15, and 30 days of the STZ icv injections, subjects were
deeply anesthetized with ketamine and xylazine and perfused
transcardially with phosphate-buffered saline (PBS) followed by 4%
paraformaldehyde in 0.1 M phosphate buffer pH 7.4 (PB). Brains
were postﬁxed and then cryoprotected in a 30% sucrose solution in
PB. Coronal sections (30 μm) of the frozen brains were cut on a slid-
ing microtome and subjected to the ﬂuorescent Fluoro‐Jade C tech-
nique to evaluate degenerating neurons [31]. Brieﬂy, gelatin- and
chromoalumen-coated slides containing the brain sections were im-
mersed in a solution containing 1% sodium hydroxide in 80% alcohol
for 5 min and in 70% alcohol, followed by distilled water for 2 min.
Subsequently, after agitation in a solution of 0.06% potassium per-
manganate for 10 min, and washing in distilled water for 2 min, the
material was incubated in a solution of 0.001% Fluoro-Jade C
(Chemicon) in 0.1% acetic acid for 20 min, and washed three times
in distilled water. The slides were then fully dried, cleared by immer-
sion in xylene for 2–3 min, and coverslipped using DPX (Fluka,
Milwaukee, WI). Finally, the material was analyzed on a ﬂuorescence
microscope equipped with a standard ﬂuorescein ﬁlter, and digital
images were collected.
2.8. Peripheral blood glucose levels
Glycemia was measured for all subjects before surgery. Subjects
involved in evaluation of late effects of STZ administration had glyce-
mia also measured 15 and 30 days after STZ injection. Blood was col-
lected by tail prick and glycemia was measured by a strip-operated
blood glucose sensor (Accu-Check Active, Roche).
2.9. Data analysis
Reference memory water maze scores were analyzed using re-
peated measure analysis of variance (ANOVA) with Groups as the
between-subject, and Sessions and Trials as the within-subject factors
(SAS Institute, Inc., Cary, NC).Probe-test scores were analyzed using repeated measure ANOVA
having Group as the between-subject and Time Bin as the within-
subject factors.
Early effects of STZ on working memory latency and path length
for the four trials across the last pre-injection working memory
session and the working memory sessions run 0.5, 1, 2, 3, 4 and
24 h after the injection were individually compared using repeated
measures analysis of variance (ANOVA), with Group as the
between-subject, and Session and Trials as the within-subject factors
[19]. In all cases, an ANOVA was run for each individual parameter.
Late effects of STZ on working memory were evaluated by calcu-
lating the means of latency, path length, percentage of time spent
within the critical training counter and counter frequency for the
four trials across the last four days of testing with ITI of 10-min.
These scores were compared to those obtained in the last session of
training in the working memory task when the ITI was virtually
zero. An individual ANOVA was run for each score having Groups as
the between-subject factor and ITI and Trials as the within-subject
factors.
Immunoblotting optical densities bands were ﬁrst normalized in
relation to the GAPDH in each experiment and then analyzed by
Student's t-tests for independent measures in terms of changes in
protein expression levels compared to controls.
3. Results
3.1. Behavioral tests
The swim speeds of the STZ and CTL subjects did not differ signif-
icantly along the behavioral testing. Therefore, it is unlikely that dif-
ferences in other parameters reﬂect either motor or motivational
impairments.
3.1.1. Early behavioral effects of STZ
As expected, pre-STZ injection behavioral data analysis revealed
lack of signiﬁcant STZ and CTL group differences for (1) latency,
path length and time percentual within the critical training quadrant
along the 5 sessions of pre-surgical reference memory training, (2)
time spent within the critical counter and counter frequency during
the probe test, and (3) latency, path length and spatial bias towards
the session-before critical location during the working memory test,
indicating that the subjects allocation to the groups to be later
injected with either STZ or vehicle was effective since no pre-
treatment, signiﬁcant behavioral differences were observed. In addi-
tion, data showed that the surgical procedure for implantation of
the guide cannulae by itself (that occurred prior to the STZ injection)
did not interfere with performance achieved at the end of the
pre-surgical training in the reference memory task (data not shown).
Early effects of STZ on performance of the working memory task
was assessed by requiring the rats to learn a new platform location
in each of 6 sessions executed 0.5, 1, 2, 3, 4, and 24 h after STZ injec-
tion, in a matching to place procedure with four trials per session, and
by comparing these results with those of a working memory session
run just before the STZ injection. Fig. 1 shows performance in terms
of latency (Fig. 1A) and path length (Fig. 1B). Note that for comparison
purposes, data of the last working memory session prior to the injec-
tions are presented at the left panel of each ﬁgure.
Statistical analysis of the results and interaction effects are
presented in Table 1. In relation to latency scores (Fig. 1A) repeated
measures ANOVA revealed Group, Session and Trial main signiﬁcant ef-
fects. ANOVA also revealed Group×Session, Group×Trial, Session×
Trial, and Groups×Session×Trial interaction effects. In relation to
path length scores (Fig. 1B) repeated measures ANOVA revealed
Group, Session and Trial main signiﬁcant effects. ANOVA also revealed
a Group×Session interaction effect. Post hoc analyses revealed, as
expected, lack of signiﬁcant differences between performances of both
Fig. 1. Early effects of intracerebroventricular STZ or vehicle injections on distinct working memory parameters in rats. Mean values±SEM are expressing the groups' performance
in terms of latency (in seconds, A) and path length (in centimeters, B) in 4 trials, after 0.5, 2, 3, 4, and 24 h of injections. For comparison purposes, data of the last working memory
session prior to injection were presented at the left panel of each ﬁgure. Data were analyzed using repeated measures analysis of variance (ANOVA) with Sessions (before injection,
0.5, 2, 3, 4, and 24 h after injection) as the within-subject factor, and Group (CTL and STZ) as the between-subject factor. Signiﬁcance level adopted was Pb0.05.
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performance prior to STZ injection was equivalent. In contrast, post
hoc analyses revealed (1) signiﬁcant latency and almost signiﬁcant
path length Groups differences in the second trial of the session run
0.5 h after STZ injection, but lack of signiﬁcant latency and path length
differences in the remaining trials within this session (see Fig. 1A and B,
respectively), (2) no signiﬁcant Groups differences in the session run
2 h after STZ injection, and (3) signiﬁcant Groups differences in the ses-
sions run 3, 4 and 24 h after the STZ injection. As Fig. 1 shows, while in
the session run 0.5 h after STZ injection, STZ subjects exhibited disrup-
tion in acquisition (see trial 2), but not in maintenance (see trials 3 and
4) of the spatial information required for performance of the working
memory task. In the sessions run 3, 4 and 24 h after STZ injection
there was a marked disruption of acquisition and maintenance of the
spatial information.
3.1.2. Late behavioral effects of STZ
STZ injection disrupted acquisition of the spatial navigation refer-
ence memory task in the water maze, as revealed by the signiﬁcant
Group effects and by the signiﬁcant Session×Group interaction ef-
fects for latency, path length, percentage of time within the critical
quadrant and percentage of time within the critical annulus
(Fig. 2A). ANOVA also revealed a signiﬁcant Session effect for latency,
percentage of time within the critical quadrant and percentage of
time within the critical annulus. In addition, there were signiﬁcantTable 1
Early behavioral effects of STZ.
Before the test
Group Session Session/trial/
group
Session/group Ses
F 1,10 P F 5,50 P F 15,150 P F 5,50 P F 5,
LAT 14.78 0.003 7.02 0.0001 2.46 0.006 12.60 0.0001 3.03
PL 21.19 0.0001 3.01 0.02 nd nd 6.33 b0.0001 1.92Trial effects for latency and path length, and a signiﬁcant Trial×Group
interaction effect for latency. In fact, Fig. 2A shows that CTL subjects
exhibited a typical reduction of latency and path length, associated
with an increase in the percentage of time spent within the critical
quadrant and within critical annulus, along sessions. In contrast, STZ
group exhibited a much smaller (if any) reduction in both latency and
path length, and a smaller increase in the percentage of time spent
within the critical quadrant and critical annulus, thus indicatingmarked
disruption of performance (Table 2).
In the probe test, when the platform was removed, the CTL sub-
jects, as expected, spent substantial amount of time searching for
the platform in its former location indicating that the animals re-
membered that spatial information (Fig. 2B). This behavior tends to
extinguish along time bins (Fig. 2B), thus reﬂecting the ﬂexibility of
the animals to deal with the novel contingency involving the lack of
the platform. In contrast, STZ subjects exhibited a marked disruption
of performance, as reﬂected by signiﬁcant reductions of the time
spent within the critical counter, the counter frequency, the percent-
age of time spent within the critical counter, and by a close to signif-
icant reduction in the percentage of time spent within the critical
quadrant.
In the working memory task the animals learned a new platform
location every day, in a matching-to-place procedure involving 4
trials per day. At the beginning of the ﬁrst trial of each day the
platform location was unknown. However, the animals received thisPost hoc
0.5 h
Post hoc 3, 4
and 24 h
sion/trial Trial/group Trial Group Group
150 P F 3,30 P F 3,30 P F 1,10 P F 1,10 P
0.0009 4.17 0.03 112.97 b0.0001 3.03 0.05 6.66 0.03
0.01 2.99 0.05 39.32 0.0001 4.21 0.07 nd nd
Fig. 2. Late effects of intracerebroventricular STZ or vehicle injections on distinct reference memory and probe test parameters in rats, evaluated by Morris' water maze task. Mean
values±SEM of trials in the same group are expressing the performance in terms of latency (in seconds), path length (in centimeters), percent time in critical quadrant, and percent
time in critical annulus over 7 days of sessions (4 trials per session) on reference memory task (A), percent time and frequency within the critical counter in each of three 1-min
consecutive time bins in probe test (B). Data were analyzed using repeated measures analysis of variance (ANOVA) with the groups (CTL and STZ) as the between-subject factor,
and day (1 to 7 or 1 to 4), time bin (1 to 3 trials) or trial (1 to 4) as the within-subject factor. Signiﬁcance level adopted was Pb0.05.
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performance along the remaining trials within a day reﬂect the ani-
mals' ability to maintain the critical information about the platform
location in working memory. The ITI was either 10 min (along
5 days) or virtually zero min (in the last day). Repeated measures
ANOVA revealed signiﬁcant Group and Trial main effects for latency
and path length, and a signiﬁcant Trial×Group interaction effect for
latency (Fig. 3A). These ﬁgures indicate that STZ subjects exhibit dif-
ﬁculties to deal with the spatial working memory task. ANOVA also
revealed a close to signiﬁcant Group main effect for percentage of
time spent within the critical training counter and signiﬁcant Trial
and Trial×Group interaction effects for counter frequency and per-
centage of time spent within the critical counter relative to other
symmetrically located counters (Fig. 3A). These results show that
the CTL subjects search for the platform in the area of the pool
where the platform was located the day before, particularly in the
ﬁrst trial of each day then extinguishing this behavior along the
remaining trials, thus indicating that they remember the priorplatform location. In contrast, STZ group does not exhibit this pattern
of behavior, indicating that they do not remember the former plat-
form location (Fig. 3A).
Together these results indicate that subjects submitted to STZ in-
jection exhibited poorer performance in the working memory version
of the water maze task as compared to CTL subjects (Fig. 3A).
As performance of the STZ group was disrupted, the ITI was re-
duced to 0 min in order to evaluate to which extent this could led
to improvement of performance as compared to that seen when the
ITI was 10 min. However, ANOVA revealed lack of signiﬁcant effects
for ITI and its interaction with other factors, indicating that the dis-
ruption seen in STZ subjects was independent of the ITI (Fig. 3B).
3.2. Immunoblotting
Subjects injected with STZ exhibited signiﬁcant changes of the Aβ
peptide, the ratio phosphorylated Tau/total Tau, and the GFAP levels
in speciﬁc brain areas brain areas (Fig. 4 — data presented as the
Table 2
Late behavioral effects of STZ.
Reference memory
Group Session Trial Session/group Trial/group
F 1,16 P F 6,96 P F 3,48 P F 6,96 P F 3,48 P
LAT 9.64 0.05 2.93 0.02 8.43 0.001 2.63 0.05 5.08 0.01
PL 10.60 0.005 nd 13.37 b0.0001 3.42 0.004 nd
QD4 16.60 0.0009 3.91 0.001 nd 3.84 0.001 2.77 0.05
ANB 9.64 0.006 2.93 0.01 nd 2.93 0.02 2.78 0.05
Probe test
Group
F 1,13 P
TC4 13.67 0.003
F4 33.57 0.0001
QD4 17.17 0.001
Working memory
Group Trial Trial/group
F 1,14 P F 3,42 P F 3,42 P
LAT 13.86 0.002 14.63 0.0001 3.52 0.02
PL 16.34 0.001 14.63 b0.0001 nd
QDant 14.12 0.002 7.07 0.0006 3.27 0.04
TCANT nd 10.85 b0.0001 9.67 b0.0001
FANT nd 9.81 b0.0001 5.65 0.003
407T.O. Santos et al. / Physiology & Behavior 107 (2012) 401–413percentage of variation relative to controls), as revealed by optical
densitometry (Table 3). In contrast, there were no changes of ChAT
expression in any of these brain regions.
3.2.1. Aβ peptide
Animals injected with STZ, relative to controls, showed a signiﬁ-
cant increase of Aβ peptide expression in several brain regions (the
speciﬁc statistical differences are presented in Fig. 4A). As Fig. 4A
shows, there was a 40.7% increase in the expression of Aβ in the
enthorinal cortex and a 41.8% increase in the basal ganglia. In addi-
tion, the hypothalamus presented a more pronounced variation in
the peptide expression, with an increase of 86.6% relative to controls.
The hippocampus and neocortex of STZ subjects did not show signif-
icant changes in Aβ levels relative to corresponding brain regions of
CTL subjects.
3.2.2. Ratio phosphorylated Tau/total Tau
Relative phosphorylation values were calculated by the ratio be-
tween phosphorylated Tau and total Tau levels, and considered for
statistical analysis (Fig. 4B). Animals injected with STZ, relative to
CTL, showed a signiﬁcant increase of the relative Tau phosphorylation
in the majority of brain regions analyzed (the speciﬁc statistical dif-
ferences are presented in Fig. 4B).
There was a signiﬁcant increase of 63% in the relative Tau phos-
phorylation levels in the neocortex and a marked increase of 298.7%
in basal ganglia. The only structure that exhibited a decrease in
the relative Tau phosphorylation levels was the enthorinal cortex
(43.88%). Other structures, such as the hippocampus and the hypo-
thalamus presented no signiﬁcant differences in the relative Tau
phosphorylation between animals of the STZ and CTL groups.
3.2.3. GFAP
Animals injected with STZ, relative to CTL subjects, showed signif-
icant increments of GFAP expression in the neocortex, hippocampus
and basal ganglia, and a signiﬁcant decrement in GFAP expression in
the enthorinal cortex (the speciﬁc statistical differences are presented
in Fig. 4C). There was a 284.9% increase of GFAP in the neocortex,
205.71% increase in the hippocampus, and 162.8% increase in the basal
ganglia. Similarly to the observed for the relative Tau phosphorylation,the enthorinal cortex exhibited a decrease of GFAP levels (71.86%) after
STZ injections. The hypothalamus exhibited no signiﬁcant changes of
GFAP after STZ injections.
3.3. Fluoro-Jade C
Fluoro-Jade C histochemistry was used to reveal neurodegeneration
in STZ-injected animals. As expected, CTL animals did not show any la-
beling whatsoever. In contrast, STZ injected animals exhibited stained
ﬁbers and neurons in distinct brain areas, at different time points. For
instance, one day after STZ injection, Fluoro-Jade C-positive neurons
were seen in the hypothalamus, near the third ventricle, and in the
septal area. In addition, labeled perikarya and neuropil in the hippo-
campal CA1 pyramidal layer were also seen after one day of the STZ
injection (Fig. 5). Similar results were observed after 15 days, with la-
beled neurons in the striatum and labeled perikarya and neuropil in
the hippocampal CA1 pyramidal layer (Fig. 6). On the other hand, we
did not observe any staining in any brain region after 30 days of STZ
injection.
3.4. Peripheral blood glucose level
There were no signiﬁcant group differences in the peripheral
blood glucose levels at any time point after the injections (data not
shown).
4. Discussion
Our results revealed behavioral and molecular changes, with dis-
tinct time courses, that followed icv STZ injection. A disruption on
the working memory was observed as early as 3 h after injections,
which was followed by degenerative processes in the hippocampus at
1 and 15 days after STZ injections. Memory disruption increases over
time and culminates with signiﬁcant changes of βA peptide and
hyperphosphorylated Tau protein levels in distinct brain structures.
Alzheimer's disease, clinically characterized by a progressive loss
of cognitive functions, especially a pronounced decline of memory
[1], is the most common cause of dementia in aged humans and
the proportion of elderly people in world populations is gradually
Fig. 3. Late effects of intracerebroventricular STZ or vehicle injections on distinct working memory parameters in rats, evaluated by Morris' water maze task. Mean values±SEM of
trials in the same group are expressing the performance in terms of path length (in centimeters), percent time within critical counter, percent time within critical quadrant, and
frequency within the critical counter over 4 days of sessions (4 trials per session) with intertrial intervals of 10 min (ITI10) on working memory task (A) latency (in seconds)
and path length (in centimeters) in one session (4 trials) with intertrial intervals of 0 min (ITI0) and 10 min (ITI10) on working memory task (B). Data were analyzed using
repeated measures analysis of variance (ANOVA) with the groups (CTL and STZ) as the between-subject factor, and day (1 to 7 or 1 to 4) or trial (1 to 4) as the within-subject
factor. Signiﬁcance level adopted was Pb0.05.
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may play important roles in pathogenesis of AD, including changes
in energy metabolism, oxidative stress, pro-death gene activation,
and the cholinergic system [11,32]. In an attempt to understand the
pathogenesis of AD, different groups have employed both in vivo
and in vitro approaches. However, none of these models seem to actu-
ally mimic the whole disease process [33].
The hypothesis of glucose metabolism and insulin signaling dis-
ruption as a likely etiology for AD has been investigated by different
groups [5,9,11,21,22]. Behavioral and molecular ﬁndings which follow
glucose metabolism and insulin signaling disruption seem to mimic at
least some aspects of the AD. For instance, icv injection of STZ leads to
cognitive impairments in memory tasks including the Morri's water
maze, the passive avoidance, and the elevated plus-maze [26–29]. How-
ever, these studies assessed memory long after disruption of glucose
metabolism and insulin signaling, restricting tagging of the progressive
symptoms of the disease. The underlying assumption, derived fromBird
and colleagues [17] study with humans, was that the working memory
version of the Morris' water maze task is more suitable to investigate
early AD-like symptoms following icv STZ injection in animals. In the
present study, early and late effects of icv STZ injection on cognitivefunctionwere evaluated using the spatial working and the spatial refer-
encememory versions of theMorris'watermaze task, as amodel for the
disease progression.
The present results revealed different types of cognitive disrup-
tions after icv STZ injection, with distinct time courses. However,
data revealed a sustained disruption of acquisition and maintenance
of the spatial information about the platform location starting 3 h
after STZ injection. Cognitive impairments were marked and
expressed both as increased latency and path length to ﬁnd the plat-
form in any of the four trials within each session, and as a smaller im-
provement of performance along trials within each session. These
results indicate that STZ subjects exhibit substantial difﬁculties to ac-
quire and/or maintain spatial information about the platform location
along trials within a session, about 3 h or longer after the icv injec-
tion. These STZ-induced disruptions were also reﬂected on the
searching pattern in the ﬁrst trial of each session, when none of the
groups know the platform location. As far as we know, this is the
ﬁrst report of early STZ-induced disruption of rats performance in a
working memory task, which could be related to Bird and colleagues
[17] observation that patients at the earliest stages of the AD exhibit
mild short-term memory impairments. It is well known that AD is a
409T.O. Santos et al. / Physiology & Behavior 107 (2012) 401–413lengthy and progressive neurodegenerative disease. There have been
reports that the onset dementia appears clinically observed at least a
decade after the onset of the disease at the molecular level [34,35].Accordingly, atrophy in the enthorinal cortex and hippocampus may
be detected before the occurrence of clinically relevant symptoms
[36]. This lack of clinical symptoms associated with ongoing detectable
neurodegenative processesmay be related to the use of clinical tests in-
sensitive to the ongoing changes.
The behavioral disruption observed in the present study shortly
after the STZ icv injection may be a result of direct alkylating and ox-
idizing effects of this drug [37,38], which could be sufﬁciently intense
in brain regions reached by the drug to trigger neuronal death. In ad-
dition, certain brain regions might be more susceptible to the STZ ef-
fects because of ineffective defenses against DNA damage or against
reactive oxygen species. For example, the high expression levels of
transient receptor potential channels in hippocampal neurons [40]
could render them more susceptible to reactive oxygen species, thus
leading to neurodegenerative processes related to AD [41]. STZ-
induced necrosis in pancreatic beta cells results from its DNA
alkylating properties and generation of reactive oxygen species [37].
The STZ structure is similar to that of glucose, which facilitates its ac-
cess to beta cells via low-afﬁnity type 2 glucose transporter (GLUT2)
[38,42,43]. It is not known if comparable mechanisms take place in
neurons. Nevertheless, there have been reports that GLUT2 is
expressed in the nervous system, particularly in the dentate gyrus
and distinct nuclei of hypothalamus [39,44,45]. Therefore, it seems
plausible to hypothesize that STZ gets into these neurons via GLUT2
[21]. On the other hand, Grünblatt and colleagues [22] observed im-
pairments of memory in rats pre-treated with inhibitors of GLUT2
and then submitted to icv injections of STZ, suggesting that other
transporters might also be involved. Even though the present study
did not speciﬁcally address this question, it seems interesting to
note that degenerating neurons, revealed by Fluoro-Jade C, were
found in the hypothalamus one day after the STZ injection. Not sur-
prisingly, hypothalamus has been described to contain high levels of
GLUT2 [39,44]. In addition, Shoham and colleagues [46] observed an
enlargement of the third ventricle after STZ injection, consistent
with the hypothesis of neuronal loss in the hypothalamus. The results
of the present study related to early evaluations favor the idea that
the degenerative processes which follow icv STZ injection may be re-
vealed both histologically in the hypothalamus, hippocampus and
septal area from 24 h after the drug injection, and behaviorally as
early as 0.5 h after the injection, being more prominent after 3 h,
when the adequate behavioral task is employed. Even though there
are analogous cognitive changes in this animal model of AD and the
mild cognitive disruption in patients at early stages of AD, it seems
important to emphasize that this model should be seen cautiously
when compared to the human pathology.
Prior studies described the development of long-lasting learning
and memory disturbances which follow icv injection of STZ to abnor-
malities in neuronal glucose metabolism, decreased insulin receptor
and insulin resistance [5,6,21,48,49]. The results of the present
study do not conﬂict with this possibility. The late effects of STZ injec-
tion reported in the present study generally conﬁrm and extend data
of other groups using the same animal model [7,9,12,14,15]. In short,
STZ-injected animals showed impairments of performance in the ref-
erence memory version, in the probe test, and in the working memo-
ry version of the Morris' water maze task. In the reference memoryFig. 4. Late effects of intracerebroventricular STZ or vehicle injections on protein levels
in distinct brain regions measured by immunoblotting analysis (data presented as the
percentage of variation relative to controls). Samples from the homogenate containing
50 μg of protein were subjected to SDS-PAGE gel and electrotransferred to nitrocellu-
lose membranes. Graphs express changes in protein levels (percentage) of STZ group
in relation to CTL group of Aβ (A), ratio phosphorylated Tau/Tau total (B), and GFAP
(C). As a loading control GAPDH was performed in all experiments (Supplementary
Figure). eCx = enthorinal cortex, Cx = cortex, BG = basal ganglia, HPC = hippocam-
pus, and HPT = hypothalamus. Data (mean values±SEM) were analyzed using abso-
lute values obtained from optical densitometry and submitted to t-test statistical
analysis. Signiﬁcance level adopted was Pb0.05.
Table 3
Immunoblotting analysis of protein expression with densitometry.a
βA Tau GFAP ChAT
Brain areas Group Optic density P-value % of change Optic density P-value % of change Optic density P-value % of change Optic density P-value % of change
eCx CTL 1±0.082 1±0.98 1±0.64 1±0.21
STZ 1.41±0.68 0.0089 ↑ 40.7 0.56±0.054 0.0052 ↓ 43.88 0.28±0.53 0.0010 ↓ 71.86 0.88±0.12 0.6656 ↓ 11.71
BG CTL 1±0.071 1±0.193 1±0.168 1±0.036
STZ 1.42±0.104 0.0063 ↑ 41.8 3.99±1.519 0.0407 ↑ 298.7 2.63±0.71 0.0271 ↑ 162.80 0.94±0.08 0.4876 ↓ 6.45
HPT CTL 1±0.077 1±0.131 1±0.229 1±0.08
STZ 1.87±0.071 0.0001 ↑ 86.6 1.32±0.392 0.5107 ↑ 31.82 1.04±0.21 0.9126 ↑ 3.82 1.07±0.09 0.5670 ↑ 7.30
HPC CTL 1±0.016 1±0.131 1±0.157 1±0.13
STZ 0.98±0.014 0.9271 ↓ 2.06 1.62±0.276 0.0897 ↑ 61.65 3.06±0.31 0.0040 ↑ 205.71 1.05±0.06 0.7756 ↑ 4.80
Cx CTL 1±0.058 1±0.201 1±0.038 1±0.048
STZ 1.07±0.076 0.4984 ↑ 7.00 1.63±0.1221 0.0212 ↑ 63.00 3.85±0.030 0.0003 ↑ 284.90 0.83±0.11 0.1653 ↓ 17.37
a Values correspond to arbitrary densitometry units (mean±SEM). Absolute values were analyzed using Student t-test. Changes are given as percentage of STZ group in relation
to CTL group.
Fig. 5. Fluoro-Jade C histochemistry staining in distinct brain regions after 1 day of the intracerebroventricular STZ or vehicle injections. Digital images of rat brain sections showing Fluoro-Jade
C-positive neurons in the hypothalamus, septal area, and perikarya and neuropil hippocampal CA1 pyramidal layer of STZ groups, indicating the degenerating process. Scale bar=50 μm.
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Fig. 6. Fluoro-Jade C histochemistry staining in distinct brain regions after 15 days of the intracerebroventricular STZ or vehicle injections. Digital images of rat brain sections show-
ing Fluoro-Jade C-positive neurons in the striatum and perikarya and neuropil hippocampal CA1 pyramidal layer of STZ groups, indicating the degenerating process. Scale bar=
50 μm.
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subjects, there was some improvement of performance along
repeated training, indicating that STZ subjects acquired relevant in-
formation about the presence of the platform in the pool, and had a
general idea of where to ﬁnd it. This pattern of results is typical of an-
imals with hippocampal damage [19] and seems to be related to the
kind of behavioral strategy used by the animals to perform this task.
The use of multiple starting locations during training, as employed
in the present study, stimulates the use of cognitive mapping. Rats
with hippocampal damage lose their ability to use cognitive maps
but not the other strategies [47]. Thus, they usually rely on the
remaining, less precise, strategies do perform the task. These results
render plausible to hypothesize that icv STZ injection interferes
with hippocampal functions. STZ-injected rats seem to remember
some clues out of the maze and that guides them to the side of the
pool where the platform was located. In addition, STZ-injected rats
showed, over the time bin intervals, a slight increase in entry fre-
quency and time spent at the critical counter, which may suggest
that after frequent exposure to environmental stimuli they have im-
proved their ability to rescue critical information from memory.
As Olton [50] defended, tasks requiring reference memory empha-
size relevant information applicable to all trials. Thus, the Morris'
water maze task corresponds to a spatial reference memory task if
the platform position is kept constant throughout all training ses-
sions. In a different way, working memory refers to maintenance of
information about speciﬁc personal and temporal contexts. Therefore,
it maintains relevant information applicable to a speciﬁc trial that
does not apply to others. Xavier and colleagues [19], however,
defended that if a different position for the hidden platform is used
on each session, per day of training in the Morris' water maze, the
critical spatial information about the platform location would beacquired on the ﬁrst trial of every session, being applicable to the
remaining trials of that speciﬁc session but not to other sessions. In
this way, one should to consider it as a spatial working memory task.
Thus, this behavioral task would correspond to the rodents' analogous
to topographical short-term memory-sensitive task reported by Bird
and colleagues [17] that was sensitive to early stages of humans' AD.
The late effects of STZ injection on performance of the working
memory task were marked. That is, relative do CTL subjects, STZ-
injected subjects did not exhibit any improvement of performance
along trials independently on being tested with an ITI of 10 min or
even when the ITI was virtually 0 min. In other words, STZ-injected
rats did not beneﬁt from information about the platform location
obtained on the previous trials within a session. In fact, when com-
paring the results of working memory tests with ITI10 and ITI0, we
can clearly see that working memory was impaired in STZ rats only
when the intervals were 10 min. When the interval was virtually
zero, STZ rats showed a signiﬁcant improvement. This fact suggests
that the lesioned rats have some kind of information acquisition,
whereas their retention mechanisms are highly compromised.
The histochemical analysis after periods longer than 15 days, are less
conclusive. Degenerative process is visible after 15 days of the injection
but not after 30 days when the cognitive impairments are still notice-
able. This apparent disparity may suggests that in periods longer than
15 days, the neurons are going through a recovery process, a period in
which there is no longer neuronal death. Other possibility is that the
time points analyzed are critical to the efﬁciency of histochemical tech-
nique of Fluoro-Jade. The Fluoro-Jade is an acidic dye which seems to
have afﬁnity by a presumably basic molecule expressed during the de-
generation process of neurons [31]. However, the results obtained
with immunoblotting technique seem to validate this animal model as
a neurodegenerative AD-likemodel, as signiﬁcant changes of βA peptide
412 T.O. Santos et al. / Physiology & Behavior 107 (2012) 401–413and phosphorylated Tau protein levels, both major hallmarks of AD,
were observed after 30 days of drug injection. In most studies using in
vivo models for induction of AD, such as transgenic animal models or
the model of STZ icv injection, is seldom found the description of in-
creased βA or its aggregation [51]. Our work has shown, however, a sig-
niﬁcant increase of the expression of βA in the hypothalamus, entorhinal
cortex and the basal ganglia.We also observed hyperphosphorylation of
Tau, especially in the entorhinal cortex, neocortex, and basal ganglia. In
fact, Grünblatt and colleagues [22] showed that icv injection of STZ at
low doses causes the hyperphosphorylation of Tau in the hippocampus.
It is curious, however, that we did not ﬁnd changes in these molecule
levels in the hippocampus, a structure mainly related to memory func-
tion and that seems to be the target of a degenerative process, as seen
in the behavioral and histochemical analyses. On the other hand, signif-
icant changes in GFAP levels were observed in the hippocampus, as well
as in other structures, indicating that at this time point after the STZ
injection, an inﬂammatory process is installed. The increase of GFAP is
associated with oxidative and inﬂammatory reactions and, indirectly,
with neurodegeneration. Exacerbated glial response and especially an
increase in the activation of astrocytes and microglia in the vicinity of
plaques have also been reported in AD [52,53].
The cholinergic system is implicated in consolidation and recovering
of memory, and is severely disrupted in AD [1,54,55]. Previous studies
have shown, for example, a reduction in ChAT activity of [56,57] and
an increase in the function of acetylcholinesterase [58,59] in this animal
model. However, although our behavioral data on late STZ effects
showed clearly a degenerative process of structures related to memory
function, we did not ﬁnd any change of ChAT levels in our immunoblot-
ting analysis in any of the evaluated structures.
As the molecular data point sometimes to distinct directions in re-
lation to behavioral data, we can suggest that STZ acted during this
long term period in a non-lethal manner in some group of neurons
that did not undergo cell death in the initial periods after the injec-
tions. This could mean that the drug in subtoxic doses could some-
how trigger biochemical changes required for the development of a
pathological process similar to that found in AD. Occasionally, such
changes would be incompatible with cell viability and culminate in
neuronal collapse.
In conclusion, we show that icv injection of STZ triggers negative
effects on rat behavioral performance and in neurodegenerative pro-
cesses. These early processes seem to persist at the behavioral level
and might culminate with changes in molecular levels. These ﬁndings
could add information on the AD-like STZ animal model, as well as on
the mechanisms underlying neurodegenerative diseases.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.physbeh.2012.06.019.
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